Exploring the role of Wdr68 in craniofacial development in zebrafish
探索 Wdr68 在斑马鱼颅面发育中的作用
基本信息
- 批准号:8626186
- 负责人:
- 金额:$ 43.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-04-06 至 2018-03-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAgonistAnimalsAutomobile DrivingCancer EtiologyCartilageCessation of lifeComplexData CollectionDefectDevelopmentDiseaseDisease ProgressionEmbryoEmbryonic DevelopmentEndothelin-1ErinaceidaeEventFoundationsFutureGene ExpressionGene Transfer TechniquesGenesGeneticGoalsGrantHeat-Shock ResponseIn Situ HybridizationIn VitroInjection of therapeutic agentJawLifeLightLinkMAP3K1 geneMediatingMessenger RNAMethodsModalityModelingMolecularOrganismOutcomePancreatic Ductal AdenocarcinomaPathologyPathway interactionsPatternPlayPublicationsRNAReporterResearchResearch PersonnelResourcesRoleShapesSignal TransductionSignal Transduction PathwaySomitesStagingStructureStudy modelsSystemTestingTimeTransgenic OrganismsVertebratesWorkZebrafishautocrinecancer paincraniofacialgraduate studenthuman diseasein vivoin vivo Modelinhibitor/antagonistinnovationinsightknowledge basemutantnovelnovel therapeuticsoverexpressionprogramspublic health relevanceresearch studyrestorationsmall moleculesmoothened signaling pathwaysomitogenesisundergraduate studentwasting
项目摘要
PROJECT SUMMARY
Signal transduction pathways important during development are frequently associated with disease. Pancreatic
ductal adenocarcinoma (PDA) is the fourth leading cause of cancer death. The Hedgehog (Hh) pathway is
important for development and a Ras-Dyrk1b pathway downregulates autocrine Hh signaling in PDA. Wdr68
and Dyrk1b can physically interact and are important for multiple events in the zebrafish, including craniofacial
development. Wdr68 and Dyrk1b are also important for edn1 expression for craniofacial development.
Intriguingly, Wdr68 physically bridges signaling from MEKK1 to Dyrk1b suggesting the existence of Ras-
MAP3K-Wdr68-Dyrk1b signal relay systems. However, while it is clear that Dyrk1b plays a key role in
modulating Hh signaling in PDA, the role of Dyrk1b in Hh signaling during normal development is unknown.
Likewise, the role of Wdr68 in Hh signaling is unknown. Furthermore, the genetic requirements and timing for
wdr68 in edn1-mediated craniofacial development are still unclear. Therefore, the overall aim of this application
is to better define the in vivo roles for Wdr68 and Dyrk1b. Our central hypothesis is that Wdr68 is part of an
evolutionarily conserved transcriptional co-regulator complex that modulates multiple signaling events
important during embryonic and adult life. The central hypothesis will be tested through three Specific Aims.
First, we will test wdr68 and dyrk1b gene activity for roles in Hh signaling. We hypothesize that wdr68
and dyrk1b modulate Hh signaling during craniofacial development. The experimental approach will use in situ
hybridization (ISH) analysis of wdr68 and dyrk1b mutants and morphants to determine whether there are
defects in Hh signaling. We will also treat embryos with small molecule activators and inhibitors of the Hh
signaling pathway for potential restoration of jaw development. We expect to see altered levels of at least
some aspects of Hh signaling in mutants and morphants. We also expect Hh antagonists will restore cartilage
formation in wdr68 mutants. Second, we will test whether ectopic endothelin-1 (edn1) expression can
rescue the lower jaw defects in wdr68 mutant or morphant embryos. We hypothesize that ectopic edn1
expression in wdr68 mutants will restore lower jaw formation. The experimental approach will employ the
parallel approaches of edn1 expression construct injection as well as the use of a GAL4-UAS system to
overexpress edn1 in wdr68 morphants. We expect that ectopic edn1 expression will restore lower jaw
formation in wdr68 mutants/morphants. Third, we will determine the temporal requirement for wdr68
activity in craniofacial development. We hypothesize that wdr68 is required during late-somitogenesis
stages for normal craniofacial development. The experimental approach will use a heat shock inducible GFP-
Wdr68 Tg(hsp70l:GFP-Wdr68) transgenic line. Because several gene expression defects are readily detected
by 24hpf, we expect slightly earlier (by 18hpf) heat shock induction of GFP-Wdr68 to rescue transgenic wdr68-
MO animals while late heat shock (20hpf or later) to fail to rescue craniofacial development.
项目摘要
在发育过程中重要的信号转导途径经常与疾病相关。胰腺
导管腺癌(PDA)是癌症死亡的第四大原因。Hedgehog(Hh)途径
Ras-Dyrk 1b通路下调PDA中自分泌Hh信号。Wdr68
和Dyrk 1b可以物理相互作用,对斑马鱼的多个事件很重要,包括颅面
发展Wdr 68和Dyrk 1b对颅面发育的edn 1表达也很重要。
有趣的是,Wdr 68在物理上桥接了MEKK 1和Dyrk 1b之间的信号传导,这表明Ras的存在。
MAP 3 K-Wdr 68-Dyrk 1b信号中继系统。然而,尽管很明显Dyrk 1b在
虽然Dyrk 1b在PDA中调节Hh信号传导,但在正常发育过程中Dyrk 1b在Hh信号传导中的作用尚不清楚。
同样,Wdr 68在Hh信号传导中的作用也是未知的。此外,遗传要求和时间,
wdr 68在edn 1介导的颅面发育中的作用尚不清楚。因此,本申请的总体目标是
更好地定义Wdr 68和Dyrk 1b的体内作用。我们的中心假设是Wdr 68是一个
调节多种信号事件的进化上保守的转录辅助调节因子复合物
在胚胎期和成年期都很重要。中心假设将通过三个具体目标进行检验。
首先,我们将测试wdr 68和dyrk 1b基因活性在Hh信号传导中的作用。我们假设wdr 68
dyrk 1b在颅面发育过程中调节Hh信号。实验方法将在现场使用
wdr 68和dyrk 1b突变体和morphant的杂交(ISH)分析,以确定是否存在
Hh信号的缺陷。我们还将用Hh的小分子激活剂和抑制剂治疗胚胎,
可能恢复颌骨发育的信号通路。我们预计至少会看到
Hh信号在突变体和morphant中的一些方面。我们还希望Hh拮抗剂能够恢复软骨
wdr 68突变体的形成。第二,我们将检测异位内皮素-1(edn 1)表达是否能
挽救wdr 68突变体或变形体胚胎中的下颌缺陷。我们假设异位edn 1
在wdr 68突变体中的表达将恢复下颌的形成。实验方法将采用
edn 1表达构建体注射的平行方法以及使用GAL 4-UAS系统,
在WDR 68变形体中过表达EDN 1。我们预期异位的edn 1表达会使下颌骨
在wdr 68突变体/变形体中的形成。第三,我们将确定wdr 68的时间要求。
颅面发育的活动。我们推测,WDR 68在后期体节发生过程中是必需的。
正常颅面发育的阶段。实验方法将使用热休克诱导的GFP-
Wdr 68 Tg(hsp 70 1:GFP-Wdr 68)转基因株系。因为几种基因表达缺陷很容易被检测到
到24 hpf,我们预期GFP-Wdr 68的热休克诱导稍早(到18 hpf)以拯救转基因wdr 68-
MO动物,而晚期热休克(20 hpf或更晚)未能挽救颅面发育。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
DCAF7/WDR68 is required for normal levels of DYRK1A and DYRK1B.
- DOI:10.1371/journal.pone.0207779
- 发表时间:2018
- 期刊:
- 影响因子:3.7
- 作者:Yousefelahiyeh M;Xu J;Alvarado E;Yu Y;Salven D;Nissen RM
- 通讯作者:Nissen RM
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT M NISSEN其他文献
ROBERT M NISSEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT M NISSEN', 18)}}的其他基金
Genetic analysis of vertebrate hindbrain development
脊椎动物后脑发育的遗传分析
- 批准号:
6445309 - 财政年份:2002
- 资助金额:
$ 43.5万 - 项目类别:
Genetic analysis of vertebrate hindbrain development
脊椎动物后脑发育的遗传分析
- 批准号:
6726792 - 财政年份:2002
- 资助金额:
$ 43.5万 - 项目类别:
Genetic analysis of vertebrate hindbrain development
脊椎动物后脑发育的遗传分析
- 批准号:
6622331 - 财政年份:2002
- 资助金额:
$ 43.5万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 43.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 43.5万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 43.5万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 43.5万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 43.5万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 43.5万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 43.5万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 43.5万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 43.5万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 43.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)